Syncom Formulations (India) Limited (SYNCOMF.NS)
- Previous Close
13.75 - Open
13.95 - Bid --
- Ask --
- Day's Range
13.60 - 13.95 - 52 Week Range
6.05 - 18.65 - Volume
1,520,050 - Avg. Volume
1,921,345 - Market Cap (intraday)
12.972B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
39.43 - EPS (TTM)
0.35 - Earnings Date May 27, 2024 - May 31, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It also offers anemia tablet and syrup, lycopene, minerals and vitamins capsules, products for eradication of vaginal pathogens, capsules for the treatment of menopause, herbal uterine tonic, syrup for the treatment lactation insufficiency, cough suppressants, liver tonic, medicine for burning urination, and nutritional supplements. In addition, the company engages in the trading of commodities and renting of properties. Further, it exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
www.syncomformulations.com555
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: SYNCOMF.NS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYNCOMF.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYNCOMF.NS
Valuation Measures
Market Cap
12.97B
Enterprise Value
13.16B
Trailing P/E
39.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.70
Price/Book (mrq)
4.80
Enterprise Value/Revenue
5.31
Enterprise Value/EBITDA
30.30
Financial Highlights
Profitability and Income Statement
Profit Margin
10.56%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
2.5B
Net Income Avi to Common (ttm)
263.83M
Diluted EPS (ttm)
0.35
Balance Sheet and Cash Flow
Total Cash (mrq)
613.89M
Total Debt/Equity (mrq)
29.64%
Levered Free Cash Flow (ttm)
--
Company Insights: SYNCOMF.NS
SYNCOMF.NS does not have Company Insights